Wound and cell studies · 02
What did TB-500 research measure about healing?
The small laboratory-made protein piece is discussed for injury repair. This page separates changes in wounds from changes inside cells. The findings mostly used the entire protein from which this small piece was copied.
How do cells use the protein studied in TB-500 research?
Whole thymosin beta-4 holds actin, the protein that forms strands used when cells move [1]. The 1:1 pairing means one thymosin beta-4 protein holds one actin protein in reserve. Cells can draw on that reserve as they change shape and move toward an injury. TB-500 copies the section responsible for holding actin, which explains the interest in studying repair [1].
Studies relevant to your injury found increased movement in skin cells and in the cells within blood-vessel walls [5]. Cells that can develop into repair tissue also moved toward damaged areas. Scar-making cells became fewer around injuries, where researchers also found newly formed blood vessels. TB-500 hasn't been shown to reproduce all those changes just because the copy contains the actin-holding section [5].
What does TB-500 contain that interests healing researchers?
TB-500 contains the section responsible for keeping actin available when cells move [1]. Injury experiments with the larger protein also found fewer scars and more blood vessels [5]. The experiments found less inflammation, the response to injury that can bring swelling, heat, and soreness. Equal effects in your body haven't been established for the copy [5].
Which injuries improved in studies linked to TB-500?
Wound findings connected with TB-500 involved rats given whole thymosin beta-4. Researchers applied thymosin beta-4 directly to wounds; other rats received injections around the organs within the belly. The treated wounds had 42% more new skin than salt-water-treated wounds at 4 days, and up to 61% more at 7 days. These differences compare skin growth between groups; wound shrinking was also greater, by at least 11% at day 7.
The treated rats formed additional blood vessels and collagen, the protein that strengthens tissue as wounds mend. With 10 picograms, a speck too light for a kitchen scale, skin cells in laboratory dishes showed two- to three-fold increased movement [3]. Researchers measured movement doubling or tripling, without separating the number of moving cells from distance travelled. A review also described better healing of rats' injured inner-knee ligaments, which join bones [5].
Mice and rats grew hair faster after thymosin beta-4 stirred cells around hair roots into activity [5]. The stroke study used kilograms of body weight, each just over two pounds, to determine amounts. Rats regained better control of movement at 2 or 12 milligrams per kilogram; the 18 milligrams per kilogram amount did not help [4]. The shots entered the space around belly organs, and these animal findings don't predict your recovery.
Did muscle growth make animals stronger in TB-500 research?
With thymosin beta-4, developing muscle cells moved toward injuries; separate experiments found better ligament healing in rats [5]. Mice with a muscle disease received 150 micrograms twice weekly for 6 months; micrograms are tiny millionths of a gram. The injections entered the space surrounding the organs in the mice's bellies. Thymosin beta-4 increased muscle regrowth without improving strength, so extra fibers did not bring better movement [5].
How much new skin grew in wound studies linked to TB-500?
Animal studies found faster healing of skin and eye wounds with whole thymosin beta-4. Rats formed 42% more new skin than comparison rats at 4 days, and up to 61% more at 7 days [3]. Those percentages compare skin growth between groups; they don't mean that share of each wound closed. Other animal studies found similar healing changes, chiefly with the larger protein, rather than established benefit for your wound [5].
What does TB-500 research show about a torn ligament?
A review reported better healing of an injured inner-knee ligament in rats given thymosin beta-4 [5]. A tendon attaches muscle to bone, while ligaments hold bones together. The rat experiment used whole thymosin beta-4, so the observed healing cannot show repair of either structure in people given the copy.
Do the TB-500 wound studies tell me how long healing takes?
Human testing hasn't shown when healing would improve with the small copy. In rats given thymosin beta-4, new skin growth exceeded the salt-water group by 42% at 4 days and up to 61% at 7 days [3]. These percentages compare growth, rather than saying how much of each wound had closed. The rat experiment with thymosin beta-4 cannot set a waiting time for your injury.
Why do new blood vessels raise both hope and concern?
Studies with thymosin beta-4 found new blood vessels and more movement of cells lining those vessels [5]. New vessels carry blood to damaged tissue as a wound heals. The larger protein was also linked to fewer scars and less cell death in injury studies [5]. Less inflammation was reported too, meaning less of the body's response that can cause swelling and soreness.
What did studies linked to TB-500 find about blood reaching injuries?
In animals and laboratory dishes, thymosin beta-4 helped blood-vessel cells move and build new vessels [5]. Damaged tissue needs the blood carried by those vessels during repair. Growth of a tumor also needs blood, so forming new vessels raises concern as well. Human studies haven't settled whether the small copy could cause that harm to you.
Did TB-500 studies show patients had less swelling?
Thymosin beta-4 reduced release of a substance that drives swelling and soreness in cells kept in laboratory dishes [9]. That cell experiment cannot show relief from your symptoms. Animal studies also linked the larger protein to less liver scarring and less of the response causing swelling. The experiments don't show that the copy will ease your symptoms.
ACCESS / EVIDENCE BOUNDARY
Prescription access does not settle the safety signal
After a licensed clinical evaluation, Promise Peptides clinicians may prescribe TB-500 through mypromise.com; that access decision does not turn an angiogenesis mechanism into a demonstrated human benefit or resolve the tumor-related uncertainty.
Which TB-500 safety questions are still unanswered?
Some bowel and pancreas cancers contained unusually large amounts of thymosin beta-4 in laboratory tests [5]. The pancreas is a gland involved in digestion and blood-sugar control. A tumor might grow or spread more readily if cells move more and new blood vessels supply the cancer. That concern doesn't mean the small copy has been shown to cause cancer in people.
A human trial comparing the copy with other care hasn't finished checking safety [12]. A 2026 review examined TB-500 and BPC-157, another laboratory-made substance studied for injury repair [7]. Several such substances helped animals heal, without settling your treatment question, while careful studies of safety in people remained scarce. The review raised concern about serious harm and use without much official oversight.
What did the early safety study linked to TB-500 report?
No finished human trial establishes the risks that the copy poses for you [12]. In Phase 1, an early safety study, volunteers tolerated whole thymosin beta-4 at amounts up to 1260 milligrams [6]. Only occasional mild or moderate complaints were reported, without naming the symptoms. Possible help to tumor growth remains a concern [5], and uncertain research-product contents add another risk.
Why are cancer researchers concerned about TB-500 findings?
Laboratory studies linked thymosin beta-4 to cancer cells spreading and blood vessels supplying tumors [5]. Cancer could gain help from the same movement and blood supply used when tissue repairs. The copy still lacks a finished human study comparing safety [12]. For your care, this remains an unresolved concern, rather than a proved harmful result in people.
What backs claims that years of TB-500 use are safe?
No controlled human study supports safety over years of TB-500 use [12]. Possible help to tumor growth [5] and research products with uncertain contents remain concerns. People experimenting on themselves describe larger starting amounts followed by smaller amounts, without a trial checking those plans [12]. The TB-500 safety concerns need to be weighed alongside reported experiences when judging a claim about your health.
What separates research on TB-500 from research on BPC-157?
TB-500 and BPC-157 both appeared in a 2026 review of substances studied for muscle, bone, and joint repair [7]. Both are laboratory-made substances, and researchers also discuss possible use for athletic performance. Most healing findings connected with TB-500 concern whole thymosin beta-4, rather than the copy [5]. FDA has approved neither substance as a drug, and animal results don't show which helps people [12].
Different substances need their own studies, even when the same injuries interest researchers. The TB-500 and BPC-157 comparison cannot identify a better treatment for your injury. Such a claim needs a fair study comparing how people fare with each substance. Human safety gaps also remain for both substances, so similar research interest is not proof of similar results.
What does the review comparing TB-500 and BPC-157 establish?
The 2026 review discussed both substances in research about muscle, bone, and joint repair [7]. The section copied into TB-500 holds actin within thymosin beta-4, though most healing work used the whole protein [5]. The review doesn't show which substance heals people better, and neither has FDA drug approval [12].
Which human experiments used the copy called TB-500?
No human study comparing TB-500 with other care has finished [12]. Whole thymosin beta-4 was given into a vein in a Phase 1 safety study involving 40 healthy volunteers [6]. Chance determined who received the protein and who received a placebo, a preparation without the tested substance. Eye studies used the whole protein too, as did a finished heart-attack study; an earlier heart study enrolled nobody [12].